XERS Xeris Biopharma Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1867096 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.4%
TTM net income YoY58.5%
TTM EPS YoY70.0%
Revenue 3-yr CAGR34.1%
Net income 3-yr CAGR—
Margins
Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
FCF margin—
EBITDA margin13.1%
Returns
ROE-27.1%
ROA-1.6%
ROIC (approx.)31.5%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets88.5%
Debt / equity3.89x
Current ratio2.15x
Interest coverage1.70x
Cash quality & payout
Operating cash flow / net income-11.34x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M |
| Cost of revenue | $42.57M | $36.83M | $28.64M | $22.63M | $13.32M |
| Gross profit | $249.28M | $166.24M | $135.27M | $87.61M | $36.27M |
| R&D expense | $31.16M | $25.56M | $22.34M | $20.97M | $25.16M |
| SG&A expense | $182.37M | $163.48M | $146.09M | $137.75M | $125.72M |
| Operating income | $24.90M | -$33.65M | -$44.01M | -$81.94M | -$115.16M |
| Interest expense | $29.08M | $30.48M | $26.61M | $14.10M | $7.18M |
| Pretax income | $554,000 | -$57.10M | -$63.50M | -$96.08M | -$122.72M |
| Income tax | $0 | -$2.27M | -$1.25M | -$1.42M | $0 |
| Net income | $554,000 | -$54.84M | -$62.26M | -$94.66M | -$122.72M |
| EBITDA | $26.21M | -$32.42M | -$42.52M | -$80.54M | -$113.83M |
| EPS (basic) | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 |
| EPS (diluted) | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 |
| Weighted avg. shares (diluted) | 172.74M | 146.77M | 137.67M | 135.63M | 79.03M |
| Balance sheet | |||||
| Cash & equivalents | $111.04M | $75.74M | $67.45M | $126.31M | $67.27M |
| Short-term investments | — | $0 | $5.00M | $0 | $35.16M |
| Receivables | $51.05M | $40.41M | $39.20M | $30.83M | $17.46M |
| Inventory | $68.67M | $48.17M | $38.84M | $24.73M | $18.12M |
| Current assets | $240.31M | $167.66M | $156.26M | $186.82M | $142.60M |
| PP&E, net | $4.95M | $5.56M | $5.97M | $5.52M | $6.63M |
| Goodwill | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M |
| Intangibles | $88.08M | $98.92M | $109.76M | $120.61M | $131.45M |
| Total assets | $383.53M | $323.06M | $322.60M | $344.52M | $304.36M |
| Current liabilities | $109.57M | $100.44M | $95.19M | $73.62M | $79.04M |
| Short-term debt | $0 | $15.10M | $0 | — | — |
| Long-term debt | $220.34M | $217.01M | $190.93M | $187.07M | $88.07M |
| Total debt | $220.34M | $232.11M | $190.93M | $187.07M | $88.07M |
| Total liabilities | $369.84M | $352.68M | $329.38M | $299.33M | $209.13M |
| Shareholders' equity | $13.69M | -$29.61M | -$6.78M | $45.19M | $95.23M |
| Net debt | $109.29M | $156.36M | $123.48M | $60.76M | $20.80M |
| Shares outstanding | 166.22M | 149.43M | 138.13M | 136.27M | 124.87M |
| Cash flow statement | |||||
| Operating cash flow | $28.63M | -$36.98M | -$47.02M | -$102.89M | -$95.53M |
| Capital expenditure | — | — | — | — | $1.08M |
| Free cash flow | — | — | — | — | -$96.62M |
| Investing cash flow | -$696,000 | $4.88M | -$6.00M | $34.46M | $97.96M |
| Financing cash flow | $11.39M | $36.17M | -$1.61M | $127.47M | $27.25M |
| Depreciation & amortization | $1.31M | $1.23M | $1.49M | $1.40M | $1.33M |
| Stock-based compensation | $22.37M | $18.36M | $10.72M | $12.16M | $11.38M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.